| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJMRA030415 |
| P698 | PubMed publication ID | 15215485 |
| P2093 | author name string | E Rand Sutherland | |
| Reuben M Cherniack | |||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 2689-2697 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Management of chronic obstructive pulmonary disease. | |
| P478 | volume | 350 |
| Q36602325 | A model protocol for emergency medical services management of asthma exacerbations |
| Q38880954 | AIMAR survey on COPD phenotypes |
| Q24193506 | Aclidinium bromide for stable chronic obstructive pulmonary disease |
| Q24197522 | Aclidinium bromide for stable chronic obstructive pulmonary disease |
| Q34576595 | Adenosine metabolism and murine strain-specific IL-4-induced inflammation, emphysema, and fibrosis |
| Q56243502 | Advances in managing COPD related to α -antitrypsin deficiency: An under-recognized genetic disorder |
| Q34428996 | Alpha1-antitrypsin deficiency |
| Q60454286 | Anticholinergics in the Management of COPD |
| Q37640070 | Arsenic exposure from drinking water and dyspnoea risk in Araihazar, Bangladesh: a population-based study |
| Q37332258 | Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies |
| Q37525031 | Barriers to and enablers of physical activity in patients with COPD following a hospital admission: a qualitative study. |
| Q55175817 | Biomimetic nanoparticles for inflammation targeting. |
| Q38109057 | Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice? |
| Q38587534 | Carotid body oxygen sensing and adaptation to hypoxia. |
| Q37018812 | Changing the burden of COPD mortality |
| Q40242119 | Chaos to randomness: distinguishing between healthy and non-healthy lung sound behaviour |
| Q41625097 | Chronic obstructive pulmonary disease hospitalisations and mortality in Victoria: analysis of variations by socioeconomic status |
| Q83508498 | Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D |
| Q33932323 | Chronic obstructive pulmonary disease: an overview |
| Q36861614 | Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy |
| Q36791049 | Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice. |
| Q92460795 | Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis |
| Q24187613 | Combined aclidinium bromide and long-acting beta 2 -agonist for COPD |
| Q90399828 | Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD) |
| Q36281792 | Current nutrition practices in adult lung transplantation |
| Q37082579 | Defect of alveolar regeneration in pulmonary emphysema: role of lung fibroblasts |
| Q37336211 | Defining chronic obstructive pulmonary disease in older persons |
| Q37610458 | Defining disease modification in chronic obstructive pulmonary disease |
| Q34880963 | Deletion of the von Hippel-Lindau gene causes sympathoadrenal cell death and impairs chemoreceptor-mediated adaptation to hypoxia |
| Q34503139 | Detection of airflow limitation using a handheld spirometer in a primary care setting |
| Q51707540 | Dyspnea as an independent predictor of mortality. |
| Q39373760 | Effect of Zafirlukast on improving lung function in patients with chronic obstructive pulmonary diseases |
| Q35537266 | Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. |
| Q36685368 | Epidemiology and risk factors for major respiratory complications after aortic surgery |
| Q35634463 | Frailty and respiratory impairment in older persons. |
| Q37123582 | High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD. |
| Q51317842 | Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration. |
| Q36026286 | IL-18 induces emphysema and airway and vascular remodeling via IFN-γ, IL-17A, and IL-13 |
| Q36859393 | Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium |
| Q91904731 | Infecciones respiratorias |
| Q37892186 | Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease |
| Q47648795 | Integrative Medicine for Respiratory Conditions: Asthma and Chronic Obstructive Pulmonary Disease |
| Q33819300 | Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology |
| Q43972063 | Long term survival in chronic obstructive pulmonary disease after ventilation in intensive care |
| Q37115933 | Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety |
| Q36473190 | Mesenchymal cell fate and phenotypes in the pathogenesis of emphysema |
| Q36779299 | Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy |
| Q43288122 | Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease |
| Q37064510 | Most Italians attending a congress on health of elderly people do not know and do not recognize respiratory diseases |
| Q36760096 | N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease |
| Q38695841 | Oxygen sensing by the carotid body: mechanisms and role in adaptation to hypoxia. |
| Q37482431 | Peak expiratory flow as a predictor of subsequent disability and death in community-living older persons |
| Q45917632 | Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. |
| Q36508146 | Pharmacological management--inhaled treatment. |
| Q38064388 | Pharmacotherapy of lung transplantation: an overview |
| Q26786480 | Physiological impairment in mild COPD |
| Q30235227 | Plausible Roles for RAGE in Conditions Exacerbated by Direct and Indirect (Secondhand) Smoke Exposure |
| Q33770577 | Pneumocafé project: an inquiry on current COPD diagnosis and management among General Practitioners in Italy through a novel tool for professional education |
| Q37667100 | Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease |
| Q50956450 | Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS/MS: a feasibility study. |
| Q34578635 | Pulmonary hypertension in patients with treated pulmonary tuberculosis: analysis of 14 consecutive cases |
| Q38988633 | Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency |
| Q37301044 | Resistance of subventricular neural stem cells to chronic hypoxemia despite structural disorganization of the germinal center and impairment of neuronal and oligodendrocyte survival |
| Q35876360 | Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease. |
| Q34126250 | Role of CCR5 in IFN-gamma-induced and cigarette smoke-induced emphysema |
| Q42415224 | Role of Inhaled Steroids in Vascular Airway Remodelling in Asthma and COPD. |
| Q37112418 | Role of ribonuclease L in viral pathogen-associated molecular pattern/influenza virus and cigarette smoke-induced inflammation and remodeling |
| Q46491319 | Ryanodine receptors in muscarinic receptor-mediated bronchoconstriction |
| Q34992988 | Serum levels of vascular endothelial growth factor in chronic obstructive pulmonary disease |
| Q79439253 | Sputum induction in COPD--it's safe, so now what do we do? |
| Q34911219 | Standards of suitability for the management of chronic obstructive respiratory diseases |
| Q38177343 | TGF-β1 as a therapeutic target for pulmonary fibrosis and COPD. |
| Q34150956 | Tai chi mind-body exercise in patients with COPD: study protocol for a randomized controlled trial |
| Q35843820 | The Therapeutic Effects of Optimal Dose of Mesenchymal Stem Cells in a Murine Model of an Elastase Induced-Emphysema |
| Q36669465 | The challenges of chronic obstructive pulmonary diseases (COPD)--a perspective |
| Q39411799 | The relationship between coping styles and clinical outcomes in patients with COPD entering pulmonary rehabilitation |
| Q34676003 | The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease |
| Q37362620 | Therapeutic perspectives in bronchial vascular remodeling in COPD. |
| Q24187438 | Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) |
| Q38717900 | Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). |
| Q45415297 | Virus diseases in ICU patients: a long time underestimated; but be aware of overestimation |
| Q35537740 | Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial |
| Q81522945 | [Endoscopic lung volume reduction for emphysema: what are the future techniques?] |
| Q91904794 | [Respiratory infections in Emergencies] |
| Q37474870 | alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies |
Search more.